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I N T R O D U C T I O N
Gamma-hydroxybutyrate (GHB) was introduced as an anesthetic agent in 1960. In recent years, GHB has been abused as a nutritional supplement for bodybuilding, 1 a drug of abuse for euphoria, 2 a sexual enhancer, and as an incapacitator for assault. It is also being investigated for the treatment of narcolepsy 3 and the management of alcohol 4 and opiate 5 withdrawal. GHB is illegal to prescribe or sell in the United States; however, it is easily available over the Internet and through precursors sold as dietary supplements. The precursors are rapidly converted systemically into GHB: γ-butyrolactone is hydrolyzed by a peripheral lactonase, and 1,4-butanediol is oxidized by alcohol dehydrogenase to γ-hydroxybutyraldehyde, then by aldehyde dehydrogenase to GHB.
The acute effects of GHB include coma, myoclonus, and bradycardia, which resolve rapidly in the absence of complications. Many patients can be discharged within a few hours of reaching medical care. 6 Recently, we observed a prolonged illness after the discontinuation of compulsive GHB use. We describe 8 patients whose symptoms and signs of central nervous stimulation and autonomic instability followed discontinuation of GHB abuse.
M A T E R I A L S A N D M E T H O D S
Seven patients exhibiting features of sedative withdrawal among individuals discontinuing excessive GHB use were identified in a retrospective review of California Poison Control System records from the San Francisco Division. An eighth case was brought to our attention by the MiamiDade County Florida medical examiner.
We reviewed poison center records (except case 3) and medical records (except cases 5 and 6). Information was extracted using a standardized form including demographics, medical history, concurrent drug use, reason for presentation, level of GHB use, toxicology screenings, onset and duration of clinical signs and symptoms, and the recorded results of laboratory tests, electrolytes, blood cell counts, and liver function studies, which yielded no remarkable abnormalities. Evidence of GHB use was confirmed in cases 1, 2, and 3 by laboratory analysis of the product ingested or urine toxicology.
R E S U L T S
Case 1
A 24-year-old salesman with attention deficit disorder who was taking no other medications used GHB for body-
2 F E B R U A R Y 2 0 0 1 building and "to help him focus." He denied current alcohol abuse but admitted intense and frequent GHB use. The patient presented to the emergency department 6 hours after his last dose of GHB complaining of intermittent anxiety, tremor, nausea, and vomiting. The patient was initially treated with diazepam, 10 mg orally, to be taken as needed, but returned the next morning with worsening symptoms. He was oriented but reported agitation, tremor, and fearful hallucinations. Within 24 hours of admission he developed tachycardia, confusion, and extreme agitation, necessitating the use of 4-point restraints, a lorazepam drip infusion, and admission to the ICU. He was treated with large doses of sedative-hypnotic and antipsychotic medications. His course continued with intermittent episodes of tachycardia, confusion, and agitation requiring restraints until hospital day 7, when he was lucid with occasional agitation. On hospital day 10, his mentation continued to improve and the lorazepam drip infusion was tapered. On day 12, he was discharged to his family while receiving tapering doses of diazepam. During hospitalization, the patient' s family brought in 2 unlabeled, 8-oz translucent plastic bottles containing clear solutions of sodium GHB at 675 mg/mL and 255 mg/mL. Analysis was performed with modification of a gas chromatography-mass spectrometry method. 7 The estimated daily dose using the higher concentration of GHB ranged from 70 to 105 g.
Case 2
A healthy 23-year-old female college student and bodybuilder used GHB daily for 1 year for alleged anabolic effects. Six weeks before admission, she increased her dosing frequency to every 3 hours around-the-clock to prevent the anxiety and tremors she experienced without it. All symptoms were relieved by another dose of GHB. She presented to her private physician's office with anxiety, insomnia, and tremor. On admission, she exhibited tachycardia and reported increasing paranoid feelings, visual and auditory hallucinations, and agitation requiring restraint. Sedation was managed with intravenous benzodiazepine administration; the patient showed little additional improvement with other sedative-hypnotic or antipsychotic drugs. A dystonic reaction to antipsychotic drugs developed on hospital day 2 prompting an ICU admission. On hospital day 7, she began rapid improvement, no further hallucinations occurred, and she was discharged on day 9. Six months later, she remained asymptomatic without medication and finished her semester with a perfect grade point average. The GHB solution she used contained 721 mg/mL GHB. The estimated daily dose ranged from 43 to 144 g. ness of breath, frequency of urination, thirst, blackout spells, and loss of appetite. He had been using GHB every 30 minutes with the last dose 20 minutes before his arrival. He denied concurrent drug use. His pupils were dilated, and he was tremulous and anxious. The ECG showed normal sinus rhythm with left ventricular hypertrophy and questionable inferior wall ischemia. He was admitted and treated with lorazepam for agitation. Over the next 24 hours, he developed tachycardia, combativeness, visual hallucinations, and persistent tremors. The hospital course was complicated by right lower lobe pneumonia requiring endotracheal intubation and mechanical venti-
Case 3
A 24-year-old male claims adjuster presented to a crisis center complaining of auditory and visual hallucinations. He admitted heavy GHB use over 10 months and increased his use to prevent GHB withdrawal hallucinations. His last dose was just before evaluation. He exhibited no evidence of hallucinations and was released with instructions to follow up in drug rehabilitation.
Two months later, the patient presented to a detoxification unit complaining of nausea, vomiting, and diarrhea for 2 months. In addition to feeling "weak and swollen," the patient complained of diplopia, blurred vision, short- Table 1 .
Characteristics of patients experiencing GHB withdrawal.
Past
Reason Prior history of cocaine, heroin, Self-presented to ED for detoxifi-Gammasorption from Bricker Labs/ 1 tsp every hour for 6 mo metal worker and alcohol abuse; denied current cation bodybuilding, alcohol substitute drug abuse; stopped alcohol 6 wk before admission (increased GHB at that time) * Patient 1 analysis of GHB solutions 675 mg/mL and 255 mg/mL. † Patient 2 analysis of GHB solution 721 mg/mL. lation for 6 days with propofol sedation. After extubation, he continued to require benzodiazepines and antipsychotic drugs. Despite sedation he was persistently confused and hallucinating, requiring the use of leather restraints. On
2 F E B R U A R Y 2 0 0 1 hospital day 12, his symptoms were improving and lorazepam was being tapered. On day 13, he was delirious but arousable. That evening, he died after an episode of spontaneous, generalized, spastic, muscular contractions and friends. A similar withdrawal toxidrome rapidly followed the last dose of GHB. The denial of concurrent alcohol and drug abuse accompanied by the lack of social or laboratory evidence of alcoholism makes delirium tremens in the setting of alcohol withdrawal an unlikely explanation for this syndrome.
D I S C U S S I O N
GHB overdose has become a significant cause of patients with drug-induced coma presenting to EDs 6 ; however, reports of a withdrawal syndrome are rare. 2 The low incidence of dependence and the rapid onset of withdrawal symptoms are probably related to the rapid absorption and elimination kinetics of GHB. After ingestion, GHB effects can begin within 10 to 15 minutes. Absorption of GHB is capacity limited, resulting in increased time to peak levels with increased dose. A therapeutic dose (50 mg/kg) produced peak levels in 45 minutes. The elimination of GHB is rapid but saturable, culminating in a terminal half-life of 23 minutes after a 50-mg/kg dose. 9 Consequently, frequent dosing is expected to be required to maintain levels sufficient for physiologic adaptation and dependence. Our patients reported physiologic adaptation with dosing every 3 hours around-the-clock.
After dependence develops, GHB use is maintained as withdrawal symptoms threaten whenever GHB is discontinued. The approximate daily dose estimated in cases 1 and 2, where the concentration of GHB was known, ranged with an upward gaze. Cardiac arrest followed severe bradycardia despite aggressive resuscitation attempts including atropine, epinephrine, and an external pacemaker. The autopsy showed pulmonary edema and an enlarged heart (490 g) with left ventricular hypertrophy, and focal severe stenosis (75%) of the left anterior descending coronary artery, without evidence of myocardial infarction. Analysis at 36 hours post mortem showed a lorazepam level consistent with therapeutic dosing at 0.02 mg/L (0.06 µmol/L), and haloperidol was undetectable. The hospital admission urine sample contained a GHB concentration of 1,750 mg/L (17 mmol/L), consistent with unpublished spot urine levels after acute overdose (Dyer, unpublished data). Rapid clearance of GHB prevents detection beyond 12 hours after a therapeutic dose. 8 The cause of death was reported as a complication of GHB withdrawal resulting from chronic substance abuse.
A D D I T I O N A L C A S E S
The 8 cases summarized in Tables 1 and 2 demonstrate a withdrawal syndrome that begins rapidly within 6 hours of the last dose. Early symptoms of insomnia, tremor, confusion, nausea, and vomiting are mild, and medical admission to a health care facility is often delayed until more severe symptoms of agitation and hallucinations are experienced. The withdrawal syndrome progresses over the initial 2 to 3 days with mild autonomic instability manifested by tachycardia, hypertension, tremor, and diaphoresis. Central nervous system symptoms include vivid hallucinations and anxiety. Confusion, disorientation, and delirium with agitation and combative behavior occur as the syndrome progresses, often requiring 4-point leather restraints and sedation. These symptoms become episodic in nature as the syndrome wanes (Table 3) .
The patients ranged from 22 to 38 years of age, and most (88%) were employed. Bodybuilding was frequently (63%) the motivation for GHB use. Results of urine toxicology screenings were negative for common drugs of abuse except for 2 patients: No. 4 with a fractured leg had detectable opiates, and No. 7 had detectable tetrahydrocannabinol in addition to the benzodiazepines, which were prescribed therapeutically for early withdrawal symptoms. All patients reported frequent ingestion of GHB, every 1 to 3 hours around-the-clock with nighttime awakening to take doses. The duration of GHB use was 2 months to 3 years. Some patients had recently escalated their dosing frequency.
The patients exhibited a consistent abuse pattern of large frequent amounts of GHB documented by family from 43 to 144 g/d. In contrast, evaluations of GHB for narcolepsy reported neither tolerance to GHB during experimental courses of 6 months to 9 years nor withdrawal symptoms at their completion (reference 3 and Mamelak M, Baycrest Hospital Toronto Canada; personal communication, July 1998). These narcolepsy studies used total daily doses of 4.5 to 9 g per night administered as two or three 30-mg/kg doses 3 hours apart, leaving a GHB-free period of more than 12 hours. The balance between dose and dosing interval necessary to produce GHB dependence is not known, but around-the-clock dosing is a feature of our cases. GHB exerts a distinct effect at specific GHB receptors. The close structural and metabolic relationship of GHB and γ-aminobutyric acid (GABA) may also play an important role in the withdrawal syndrome. In vivo conversion of radioactive GHB into GABA has been described, and current research has proposed that GHB modulates both GABA A and GABA B receptors. 10, 11 The end result, acutely, is neuroinhibition with physiologic tolerance developing over time.
Clinical similarities between GHB withdrawal and other sedative hypnotic withdrawal syndromes suggest a common mechanism (Table 4) . Ethanol increases endogenous levels of GHB and acts synergistically with GHB to produce central nervous system and respiratory depression. 12 Cross-tolerance has been demonstrated between ethanol and GHB in rats, and GHB has been used to suppress acute alcohol withdrawal symptoms. 13 Chronic alcohol, benzodiazepine, and GHB administration downregulate inhibitory GABA receptors. [14] [15] [16] Diminished GABA synaptic activity releases excitatory neurotransmitters and pathways from inhibition and likely plays an important role in the subsequent withdrawal syndrome. 17 One may also speculate that an excess dopaminergic state, known to be associated with psychotic hallucinosis, 18 may be part of the GHB withdrawal syndrome. Baclofen, a GABA B receptor agonist, has been associated with severe psychological reactions during withdrawal. 19, 20 The differential diagnosis for GHB withdrawal syndrome includes the other sedative, hypnotic, or alcohol withdrawal syndromes (Table 4) . Conversely, GHB withdrawal can resemble acute drug intoxication by sympathomimetic agents, as well as serotonin syndrome and neuroleptic malignant syndrome. Altered mental status may result from metabolic causes such as thiamine deficiency caused by poor nutritional balance from dieting, weight training programs, or when GHB has been used as an ethanol substitute. Endocrine abnormalities including thyroid storm and pheochromocytoma should be considered. Bodybuilders who abuse GHB may also abuse injectable steroids, which increase their risk of infectious complications through needle sharing and steroid psychosis.
Management of GHB withdrawal is symptomatic and supportive, stressing sedation to prevent injury, hyperthermia, and rhabdomyolysis. Benzodiazepines effectively sedate, although extremely high doses may be required. Barbiturates have been shown to be effective in the treatment of refractory cases of GABA-minergic withdrawal. Propofol has also been used successfully. However, unpublished cases using valproic acid, which has been shown to raise endogenous GHB levels in rat brain, 21 or baclofen, the GABA B agonist, did not dramatically alter the withdrawal course. Animal studies are needed to analyze the cross-tolerance of GHB to other sedatives, the 
